Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Abstract
Drugs acting at metabotropic glutamate receptors (mGluRs) are among the most promising agents under development for the treatment of psychiatric disorders. The research in this area is at a relatively early stage, as there are no drugs acting at mGluRs that have been approved for the treatment of any psychiatric disorder. However, in the areas of schizophrenia, anxiety disorders and mood disorders, research conducted in animal models appears to translate well into efficacy in human laboratory-based models of psychopathology and in preliminary clinical trials. Further, the genes coding for mGluRs are implicated in the risk for a growing number of psychiatric disorders. This review highlights the best studied mGluR strategies for psychiatry, based on human molecular genetics, studies in animal models and preliminary clinical trials. It describes the potential value of mGluR2 and mGluR5 agonists and positive allosteric modulators for the treatment of schizophrenia. It also reviews evidence that group II mGluR agonists and positive allosteric modulators as well as group I mGluR antagonists might also treat anxiety disorders and some forms of depression, while mGluR2 and group I mGluR antagonists (particularly mGluR5 antagonists) might have antidepressant properties. This review also links growing insights into the role of glutamate in the pathophysiology of these disorders to hypothesized mGluR-related treatment mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early studies have shown that inhibitors of glutamate release attenuate the ketamine-induced psychotomimetic symptoms [20][21][22][23].”
From The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects (2018) · cites this paper as [22]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationHasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Research works printed but not linked: 16
- Chambers, 1999, Semin Clin Neuropsychiatry, 4, 274
- Sanacora, 2008, Nature Rev: Drug Discov, 7, 426
- Pietraszek, 2004, J Physiol Pharmacol, 55, 587
- Rodriguez, 2007, Curr Opin Drug Discov Devel, 10, 715
- Fujii, 2003, Psychiatr Genet, 13, 71
- Farber, 1999, Schizophr Res, 36, 308
- Moghaddam, 1998, Science, 281, 1349, 10.1126/science.281.5381.1349 · DOI · Paper page
- Klodzinska, 2004, J Physiol Pharmacol, 55, 113
- Stachowicz, 2006, Pharmacol Rep, 58, 820
- Stachowicz, 2005, Pharmacol Rep, 57, 856
- Michelson, 2005, Neuropharmacology, 49, 84
- Mason, 2001, Biol Psychiatry, 49, 148S
- Krystal, 2008, Int J Neuropsychopharmacology, 11, 73
- Krystal, 2007, Swiss Med Wkly, 137, 215
- Palucha, 2002, Pol J Pharmacol, 54, 581
- Legutko, 2006 May-Jun, Pharmacol Rep, 58, 427
Cited by
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
“Positive and negative allosteric modulators of metabotropic glutamate receptors, which can influence glutamate release and extracellular glutamate levels, have also been shown to have antidepressant-like action”
BackgroundPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“Several preclinical studies have reported anxiolytic effects of mGluR modulators (120), although human studies have not been as promising.”
BackgroundSelf-citationAbdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Self-citation50 years of hurdles and hope in anxiolytic drug discovery
Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 414
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
“mGluR2 agonists have anxiolytic activity in animals and humans (120).”
BackgroundSelf-citation
Metadata
- Authors
- Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S.
- Affiliations
- Yale University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Krystal, John H.
- Venue
- CNS Drugs
- Published
- 2010-08
- Volume
- 24
- Issue
- 8
- Pages
- 669-693
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2031258646
- Cited by
- 180
- References
- 221
- Citations by year
- 2026: 3 · 2024: 11 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 8 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 12 · 2015: 10 · 2014: 20 · 2013: 14 · 2012: 38
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k05aa014906-03)
- National Institute on Alcohol Abuse and Alcoholism (K05 AA 14906-01, R01AA011321, I-P50 AA-12870, P50AA012870)
- National Institute of Mental Health (K23MH069656, P50MH068789, P50MH044866)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- metabotropic glutamate receptors, mGluR agonists, mGluR antagonists, mGluR2, mGluR5, positive allosteric modulators, schizophrenia, anxiety disorders, depression, mood disorders, glutamate, psychiatric drug development
- MeSH terms
- Animals, Antidepressive Agents, Anxiety Disorders, Central Nervous System Agents, Humans, Schizophrenia, Antipsychotic Agents, Anti-Anxiety Agents, Receptors, Metabotropic Glutamate, Mood Disorders, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. https://app.cochat.ai/papers/10.2165/11533230-000000000-00000
- The paper
- Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010). Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs. https://doi.org/10.2165/11533230-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.